This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Correia, M. L.G. Articles by Haynes, W. G. Search for Related Content PubMed PubMed Citation Articles by Correia, M. L.G. Articles by Haynes, W. G. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2183.)
© 2006 American Heart Association, Inc.

Editorials

A Role for Plasminogen Activator Inhibitor-1 in Obesity: From Pie to PAI?

Marcelo L.G. Correia; William G. Haynes

From the General Clinical Research Center and Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City.

Correspondence to William G. Haynes, MBChB, MD, Divisions of Clinical Pharmacology and Cardiovascular Diseases, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242. E-mail william-g-haynes@uiowa.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The regulation of fibrinolysis depends on the interaction of plasma fibrinolytic and anti-fibrinolytic proteins. Fibrinolysis depends on the enzymatic conversion of plasminogen to plasmin. This process is mediated by tissue-type and urokinase-type plasminogen activators (t & uPAs, respectively).

See page 2209

Plasma antifibrinolytic activity is primarily regulated by plasminogen-activator inhibitors (PAIs).¹ Four PAIs have been described: PAIs-1 through 3 and protease nexin. Importantly, PAI-1 is the main antagonist of t & uPAs, accounting for approximately 60% of the inhibition of plasminogen activators. PAI-2 mostly inhibits urokinase plasminogen activator (uPA), whereas protease nexin antagonizes plasmin, thrombin, and uPA. The antifibrinolytic activity of PAI-3 is uncertain. These molecules and others are also collectively known as serine protease inhibitors or "serpins".

PAI-1 is a single chain 45-kDa glycoprotein that contains from 379 to 381 amino acids. Endothelial and vascular smooth muscle cells are presumably the main sources of PAI-1 but other cells, such as platelets, hepatocytes, mesangial cells, fibroblasts, monocytes, macrophages, adipocytes, and stromal cells permeating the adipose tissue, have also been shown to secrete the serpin. The gene for PAI-1 is located on chromosome 7q21.3-q22, and its expression is mainly regulated at the transcriptional level through the action of several hormones [eg, renin-angiotensin-aldostrerone system (RAAS)], cytokines [eg, tumor necrosis factor (TNF) ], lipoproteins (eg, VLDL), glucose, and endotoxin.¹

Polymorphisms that influence PAI-1 gene expression have been described. The single 4/5 guanine polymorphism (4G/5G) in the promoter region of PAI-1 gene is widespread and has been associated with variable plasma PAI-1 activity and . . . [Full Text of this Article]

Related Article:

Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1

David L. Crandall, Elaine M. Quinet, Soulaf El Ayachi, Amy L. Hreha, Courtney E. Leik, Dawn A. Savio, Irene Juhan-Vague, and Marie-Christine Alessi
Arterioscler Thromb Vasc Biol 2006 26: 2209-2215. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				S. M. Nelson, N. Sattar, D. J. Freeman, J. D. Walker, and R. S. Lindsay Inflammation and Endothelial Activation Is Evident at Birth in Offspring of Mothers With Type 1 Diabetes Diabetes, November 1, 2007; 56(11): 2697 - 2704. [Abstract] [Full Text] [PDF]